Author:
Wu Peiliang,Li Wenya,Cai Xueding,Yan Hanhan,Chen Mayun
Funder
Alzheimer's Disease Neuroimaging Initiative
National Institute on Aging
National Institute of Biomedical Imaging and Bioengineering
bbVie, Alzheimer’s Association
Alzheimer’s Drug Discovery Foundation;
Araclon Biotech;
BioClinica, Inc.;
Biogen; B
ristol-Myers Squibb Company
CereSpir, Inc.;
Cogstate;
Eisai Inc.; E
lan Pharmaceuticals, Inc.
Eli Lilly and Company;
EuroImmun; F
. Hoffmann-La Roche Ltd. and its affiliated company
Genentech, Inc.;
Fujirebio;
GE Healthcare;
IXICO Ltd.; J
anssen Alzheimer Immunotherapy Research & Development, LLC.
Johnson & Johnson Pharmaceutical Research & Development LLC.;
Lumosity;
Lundbeck;
Merck & Co., Inc.; M
eso Scale Diagnostics, LLC.
NeuroRx Research;
Neurotrack Technologies;
Novartis Pharmaceuticals Corporation;
Pfizer Inc.;
Piramal Imaging;
Servier;
Takeda Pharmaceutical Company; and
Transition Therapeutics. The
Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the F
oundation for the National Institutes of Health